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Summary
By interacting with hundreds of protein partners, 14-3-3 proteins coordinate vital cellular 
processes. Phosphorylation of the small heat shock protein HSPB6 within its intrinsically 
disordered N-terminal domain activates its interaction with 14-3-3, ultimately triggering smooth 
muscle relaxation. After analyzing the binding of an HSPB6-derived phosphopeptide to 14-3-3 
using isothermal calorimetry and X-ray crystallography, we have determined the crystal structure 
of the complete assembly consisting of the 14-3-3 dimer and full-length HSPB6 dimer and further 
characterized this complex in solution using fluorescence spectroscopy, small-angle X-ray 
scattering and limited proteolysis. We show that selected intrinsically disordered regions of 
HSPB6 are transformed into well-defined conformations upon the interaction, whereby an 
unexpectedly asymmetric structure is formed. This structure provides the first-ever atomic 
resolution snapshot of a human small HSP in functional state, explains how 14-3-3 proteins 
sequester their regulatory partners, and can inform the design of small-molecule interaction 
modifiers to be used as myorelaxants.
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Introduction
Although the ability of proteins to fold into a well-defined three-dimensional structure had 
been traditionally considered a prerequisite of their physiological activity, it was realized 
recently that functionally vital proteins often include regions lacking a defined three-
dimensional structure. Rapidly growing evidence indicates that such intrinsically disordered 
regions (IDRs) play central roles in protein-protein interactions (Tompa et al., 2015), such as 
those mediated by the 14-3-3 proteins, key nodes of the eukaryotic signaling network 
(Pozuelo Rubio et al., 2004; Uhart and Bustos, 2013). These abundant proteins, amounting 
up to 1.3 % of the proteome mass in some tissues, are widely recognized as coordinators of 
multiple processes such as cell proliferation, transcription, hormonal production and 
apoptosis (Aitken, 2006; Pozuelo Rubio et al., 2004). Eukaryotes typically carry several 
14-3-3 isoforms (seven in humans), which form homo- and heterodimers (Aitken, 2006). In 
cellulo, the 14-3-3 proteins interact with over 700 partners, including transcription factors, 
receptors, protein kinases, phosphatases, proapoptotic proteins and certain enzymes 
(Pozuelo Rubio et al., 2004; Uhart and Bustos, 2013).
An important partner of the 14-3-3 proteins is HSPB6 (also known as HSP20) (Chernik et 
al., 2007; Dreiza et al., 2005) belonging to the small heat shock proteins (sHSPs), a large 
group of ATP-independent cellular chaperones (Mymrikov et al., 2011). HSPB6 consists of 
a rigid  ?-crystallin domain (ACD) flanked by N- and C-terminal domains (NTD and CTD) 
that have a high degree of intrinsic disorder (Mymrikov et al., 2011; Weeks et al., 2014) 
(Fig.1a). Unlike most members of the sHSP family forming high-order oligomers, HSPB6 is 
stable in a dimeric state (Bukach et al., 2004; Sluchanko et al., 2011; Weeks et al., 2014). 
Interaction between the 14-3-3 proteins and HSPB6 (Chernik et al., 2007; Dreiza et al., 
2005) is dependent on the phosphorylation of the latter by cyclic nucleotide-dependent 
protein kinases (Furnish et al., 2010; Komalavilas et al., 2008) at a characteristic motif 
centered at residue Ser16 (Dreiza et al., 2005; Yaffe et al., 1997). This motif, RRApSAP, 
follows the ÔcanonicalÕ pattern for 14-3-3 binding, (R|K)X2-3(pS|pT)X(P|G), meaning that a 
positive charge is required 3-4 residues upstream, and a Pro or Gly residue two residues 
downstream of the phosphorylated Ser or Thr, while the X positions are not strictly defined 
(Yaffe et al., 1997). As a result, a stable 90 kDa heterotetramer consisting of the 14-3-3 and 
phosphorylated HSPB6 (pHSPB6) dimers is formed (Chernik et al., 2007; Sluchanko et al., 
2011). The  ? isoform of human 14-3-3 was previously reported to bind pHSPB6 with 
micromolar affinity (Sluchanko et al., 2011). Being a major substrate for several protein 
kinases, HSPB6 was hypothesized to act as a phosphoswitchable displacer of other 
regulatory proteins from 14-3-3 complexes, which should affect the balance of the whole 
14-3-3 interactome (Pozuelo Rubio et al., 2004; Uhart and Bustos, 2013). Interestingly, 
another abundant cellular 14-3-3 partner, vimentin, has also been proposed to sequester the 
14-3-3 proteins and displace their other targets in vivo (Tzivion et al., 2000). In line with this 
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model, controlling the 14-3-3/pHSPB6 interaction was shown to be crucial in a number of 
pathological conditions requiring smooth muscle relaxation, such as subarachnoid 
hemorrhage, asthma and hypertension (Furnish et al., 2010; Komalavilas et al., 2008). 
Indeed, an HSPB6-derived phosphopeptide AZX100¨ (Fig.1a) was able to partially 
reproduce the relaxation-promoting effect of the full-sized phosphorylated protein (Arno et 
al., 2014; Furnish et al., 2010; Lopes et al., 2009). It has been suggested that this effect may 
be due to HSPB6-induced displacement of phosphocofilin from the 14-3-3 complex, 
followed by cofilin activation by dephosphorylation and actin cytoskeleton remodeling 
(Dreiza et al., 2005). However, direct 14-3-3/phosphocofilin interaction could not be 
confirmed in vitro (Sudnitsyna et al., 2012). It is therefore likely that there are other binding 
partners of 14-3-3, such as phosphatases acting on cofilin in particular, which could be 
released from the 14-3-3 complex by pHSPB6, providing for an efficient control of cofilin 
activation (Sudnitsyna et al., 2012).
Here we have sought a detailed structural and biophysical insight into the interaction 
between phosphorylated HSPB6 and 14-3-3 proteins. These efforts have culminated in the 
determination of the atomic structure of the complete regulatory complex of these proteins, 
both in crystals and in solution. This resolves a long-standing challenge in the field, related 
to the difficulty of crystallizing proteins with prominent, functional IDRs. Indeed, no atomic 
structures of full-length mammalian sHSPs in either free or complex form could be 
determined until now. At the same time, atomic resolution data on the interaction of 14-3-3 
with partners have been limited to a number of 14-3-3 complexes with short 
phosphopeptides as well as a single larger complex involving truncated arylalkylamine N-
acetyltransferase in a non-natural stoichiometry (PDB entry 1IB1). The structural data 
obtained here shed light on the molecular mechanism of action of phosphorylated HSPB6 in 
the context of its competition with other regulatory partners of 14-3-3 proteins.
Results
Binding of HSPB6 phosphopeptides to the 14-3-3 proteins
To better understand the primary interaction between 14-3-3 and pHSPB6 at molecular level, 
we have employed two synthetic phosphopeptides which correspond to HSPB6 residues 
13-20 and 11-23 respectively (Fig.1a). Importantly, the latter is equivalent to the active C-
terminal moiety of the AZX100 peptide (Lopes et al., 2009). Isothermal titration calorimetry 
(ITC) experiments have shown that phosphopeptide 11-23 binds to 14-3-3 ? the predominant 
isoform in muscle tissue (Horie et al., 1999), with an apparent KD of 2.3 ± 0.3 µM. A similar 
value was obtained with the human 14-3-3 ? isoform (KD = 6.3 ± 0.5 µM; Fig.1b), and both 
complexes showed the expected stoichiometry of one peptide per 14-3-3 subunit. It should 
be noted that these interactions are stronger than, for instance, binding of phosphopeptides 
of C-RAF (KD=16.7 ± 2.0 µM with 14-3-3 ?(Molzan and Ottmann, 2012)) and p53 (KD 
=16.3 ± 0.7 µM with 14-3-3 ?(Schumacher et al., 2010)). The strength of the primary 
interaction hints towards a highly stable complex between the full-length phosphorylated 
HSPB6 and 14-3-3, as indeed could be shown below.
We have also co-crystallized human 14-3-3 ? with both phosphopeptides 13-20 and 11-23 
and determined the atomic structures of the resulting complexes at 2.4 and 2.5 resolution, 
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respectively (Tables 1 and S1). The peptides bind in the characteristic groove of the 14-3-3 
molecule in identical conformations (Fig.1c). Also for the longer peptide, only residues 
13-20 were found ordered in the electron density map, suggesting that the upstream and 
downstream residues are mobile and not critically involved in the binding. The phosphate 
moiety forms salt bridges with the conserved 14-3-3 ? residues Arg56 and Arg129 and is H-
bonded to Tyr130 (Fig.1c). The main-chain atoms of the residues immediately adjacent to 
the phosphoserine, i.e. Ala15 and Ala17, are H-bonded to 14-3-3 residues Asn226 and 
Asn175, respectively. In addition, stabilizing interactions are observed within the 
phosphopeptide itself, as Arg14 directly coordinates the phosphate group of pS16 (and also 
forms a salt bridge with Glu182 of 14-3-3), while the residues Arg13 and Ala17 are each H-
bonded to the phosphate via ordered water molecules. Finally, residues Leu19 and Pro20 of 
the peptide pack against a rather apolar side of the  ?3 helix of 14-3-3 near residue Val46 
(Fig.1c).
Interaction between the full-length pHSPB6 and 14-3-3
Next, we have analyzed the binding of phosphorylated HSPB6 to 14-3-3 in physiological 
solution, in which both proteins are predominantly present as dimers (Bukach et al., 2004; 
Chernik et al., 2007; Sluchanko et al., 2011). ITC measurements were done but revealed a 
complex thermal pattern which was difficult to interpret, supporting a multistage process of 
complex assembly (see Discussion). Instead, fluorescence spectroscopy has been used. To 
this end, phosphorylated full-length HSPB6 was stoichiometrically labeled at its unique 
Cys46 residue with an environmentallysensitive 1,5-I-AEDANS moiety. Upon titration with 
14-3-3 ?, the fluorescence peak of pHSPB6AEDANS shifted from 486 to 479 nm and its 
amplitude increased up to a saturation point (Fig.2a). Analysis of the resulting binding curve 
(Fig.S1) yielded an apparent KD of the 14-3-3 ?/pHSPB6AEDANS complex at 0.56 ± 0.2 µM. 
This value suggests that the interaction of 14-3-3 ? with intact pHSPB6 is significantly 
stronger than the interaction with the isolated HSPB6 phosphopeptide described above. In 
line with that, the following titration of the saturated 14-3-3 ?/pHSPB6AEDANS complex with 
increasing amounts of the 11-23 phosphopeptide revealed a sigmoidal decay in the 
fluorescence signal with an IC50 of 28.9 ± 0.9 µM (Fig.2b), indicating that only excessive 
concentrations of the phosphopeptide could expel pHSPB6 from the complex. Moreover, 
titration of the AEDANS-labeled pHSPB6 by 14-3-3 ? in the presence of equimolar 
concentration of the phosphopeptide and even a 7-fold excess of the latter also resulted in a 
saturable curve (Fig.2b), suggestive of a retained 14-3-3 ?/pHSPB6AEDANS interaction. 
These competition experiments have also allowed an independent estimate of an apparent 
dissociation constant for the 14-3-3 ?/phosphopeptide interaction at 5.2 ± 0.5 µM, in good 
agreement with our ITC data (Fig.1b).
Crystal structure of the complete 14-3-3/pHSPB6 complex
The main challenge of this study was to determine the atomic structure of the regulatory 
complex formed by the full-length 14-3-3 and pHSPB6. To this end we have systematically 
attempted the crystallization of highly pure complexes formed by recombinant in vivo 
phosphorylated HSPB6 with each of the seven human 14-3-3 isoforms. This yielded 
reproducible crystals for the 14-3-3 ? isoform complex only (Table S1), where the initial 
diffraction was limited to ~8 resolution. At this point, we have designed two mutants of 
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14-3-3 ? using the surface entropy reduction approach (Goldschmidt et al., 2007) (designated 
Clu1 and Clu3, each carrying a replacement of three consecutive residues to alanines, see 
Experimental Procedures) as well as HSPB6 variants with short terminal truncations. Using 
these mutants as well as scanning >100 crystals at a microfocus synchrotron radiation 
beamline eventually allowed us to improve the resolution to 4.5 (Table 1) and determine 
the crystal structure of the full complex.
There are three 14-3-3 ?/pHSPB6 complexes per asymmetric unit of the crystals. Despite 
differences in the crystal lattice contacts made by each of the complexes, the overall 
structure of the three is very similar (Fig.S2a). The binding of pHSPB6 does not cause any 
major conformational changes in the 14-3-3 dimer (C ? r.m.s.d. 0.90 compared to the 
phosphopeptide-bound structure). Remarkably, while both phosphorylated N-terminal IDRs 
of HSPB6 interact with the binding grooves of the 14-3-3 dimer in the same way, the ACD 
dimer of HSPB6 attaches to only one 14-3-3 subunit resulting in an unexpected asymmetric 
structure (Figs.3a, b). The binding involves two C-terminal  ?-helices of the 14-3-3 molecule 
forming an antiparallel motif, and three surface loops (connecting the strands  ?3- ?4,  ?5- ?7 
and  ?8- ?9 respectively) of the nearest ACD. The binding interface features a salt bridge 
between Arg224 (14-3-3) and Glu86 (HSPB6) and masks about 4002, corresponding to 
4.3% of the total accessible surface of the ACD dimer, suggesting that this interface is 
specific (see Fig.S2b for additional detail).
The structure of the 14-3-3 ?/pHSPB6 complex reveals that the  ?-sandwich ACD of HSPB6 
dimerizes via the APII type interface of the aligned  ?7 strands (Laganowsky et al., 2010), 
confirming a hypothesis that this is the preferred dimerization mode for mammalian ACDs 
(Baranova et al., 2011; Hochberg et al., 2014; Mymrikov et al., 2010). The ACD dimer 
features a relatively flat common  ?-sheet resulting from the  ?7- ?7 alignment (Fig.3d), just 
like that found in the crystal structure of HSPB6 ΔN56 truncation (Weeks et al., 2014) (C 挀 
r.m.s.d. 0.79 after superimposing dimers), rather than a curved shape that had been 
suggested from solid-state NMR data for  ?B-crystallin (Jehle et al., 2010). In addition, our 
new structure shows that, in the full-length HSPB6, the ACD fold starts with strand  ?3 
(residues 74-79), in contrast to HSPB1 and HSPB5 which seem to contain an additional 
short strand  ?2 (Hochberg et al., 2014).
Ordering of functional IDRs upon the complex formation
Importantly, the obtained 4.5 electron density map of the 14-3-3 ?/pHSPB6 complex 
reveals several functionally relevant regions of the HSPB6 NTD (residues 1-71). In each of 
three complexes found in the crystallographic asymmetric unit, residues 1 to 20 of both 
NTDs as well as residues 27 to 38 of one of the NTDs could be traced. In addition, in one of 
the six NTDs, residues 21 to 26 were additionally traced, so that the structure of the entire 
region encompassing residues 1 to 38 could be established.
First, both phosphoserine-containing regions of the HSPB6 dimer were found to bind in the 
corresponding 14-3-3 grooves (Fig.3a), in a conformation virtually identical to that observed 
in the 14-3-3/phosphopeptide 13-20 complex (C ? r.m.s.d. of 0.15 for residues 14-19). The 
observed structure thus confirms the hypothesis that HSPB6 fully sequesters the 14-3-3 
dimer making it unavailable for interaction with other phosphorylated partners.
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Second, we could trace the very N-terminal residues 1-12 of both HSPB6 chains, which 
accommodate distinct conformations (designated as type I and II, see Figs.3a,b). 
Interestingly, we have found that the type I N-terminus ÔpatchesÕ the  ?4/ ?8 groove on the 
side of the nearest ACD within one heterotetramer, whereas the type II chain engages in a 
similar patching across a crystal lattice contact (Figs.3a and S2). In each case, the residues 
V5 and V7 insert into the hydrophobic core of the ACD (Fig.3c). Moreover, we could obtain 
an independent insight into this phenomenon by co-crystallizing the isolated ACD domain of 
HSPB6 (residues 72 to 149) with an N-terminal peptide of HSPB6 which corresponds to 
residues 2 to 10 (EIPVPVQPS, N-peptide). The resulting crystal structure at 2.6 resolution 
readily reveals the patching of the  ?4/ ?8 grooves at either side of the ACD dimer by well-
ordered peptides (Fig.3c), fully confirming the patching mechanism observed in the 
14-3-3 ?/pHSPB6 complex (Fig.S2c). Previously, such patching of the  ?4/ ?8 grooves by 
hydrophobic residues has been observed mainly for the C-terminal IPI/V motif (Delbecq et 
al., 2012; Hochberg et al., 2014; Weeks et al., 2014), which is present in most human sHSPs 
but missing in HSPB6. Here we show that the unusual N-terminal 3IPVPV7 motif of HSPB6 
(Weeks et al., 2014) is also capable of such patching, which could be the case in the free 
HSPB6 dimer as well.
Most interestingly, the crystal structure of the 14-3-3 ?/pHSPB6 complex also reveals the 
RLFDQxFG motif (HSPB6 residues 27-34) which is the sole highly conserved region within 
the NTD of vertebrate sHSPs (Heirbaut et al., 2014). We have found that in the type I chain 
this motif becomes ordered upon its insertion into the distinct shared groove of the ACD 
dimer formed by the two  ?3 strands (Bagneris et al, 2009) (Figs.3b,d). Such an insertion is 
favored by the interaction of the negatively charged Asp30 residue and the positive potential 
at the floor of the shared groove (Fig.3e). The groove has room for only a single copy of the 
motif. Correspondingly, per heterotetramer, only one conserved NTD motif (in type I chain) 
was found in the bound state, while the second motif (in type II chain) remains disordered. 
The proximal half of the NTD (residues 39-69) is disordered in all chains, leaving an 
ambiguity in the interconnection of the N-terminal parts and the ACDs (see Fig.3b for 
details).
Solution data on the 14-3-3/pHSPB6 complex
The tracing of the NTD within the 14-3-3/pHSPB6 complex could also be verified in 
solution using limited proteolysis. Free HSPB6 is most efficiently cleaved by trypsin at 
residues R13 and R14, but in the complex with 14-3-3 ? this cleavage is considerably slower 
(Fig.4a and Fig.S3). This is in line with our structural data, as the residues are clearly 
protected once bound within the phosphomotif-binding groove (see Fig.3a). In contrast, the 
cleavage at residues R27 and R32 proceeds with nearly the same efficiency in both free and 
complexed pHSPB6, although at a yet slower rate than the cleavage at R13/R14 within the 
complex (Fig.4a). This implies that residues R27 and R32 are quite protected both in the free 
HSPB6 dimer and the complex.
Finally, we have used small angle X-ray scattering (SAXS) data from the 14-3-3 ?/pHSPB6 
complex in solution to model its complete molecular structure. A dimensionless Kratky plot 
of the scattering data (Fig.S4a) revealed a pronounced peak characteristic for globular 
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proteins and no significant rise towards higher s values, suggesting that the overall 14-3-3 ?/
pHSPB6 complex is rather rigid. To model the complex, the obtained crystal structure has 
been supplemented with the missing parts of the two NTDs (11% of total residues in the 
complex) towards maximizing the fit between the experimental data and the SAXS curve 
calculated from the full-atom model. A model producing good fit could be achieved, with  ?2 
value of 2.2 for the full range of scattering data (Fig.4b, S4). Alternative models (see Fig. S5 
and Experimental Procedures) failed to yield a satisfactory fit. These results indicate that the 
crystallographic structure is principally preserved in solution, whereby both NTDs, while 
being inherently dynamic, accommodate relatively compact conformations and reside within 
the open cavity formed by the interacting 14-3-3 and ACD dimers (Fig.4c).
Druggable pockets within the 14-3-3/pHSPB6 interface
Computational analysis of the 14-3-3 ?/pHSPB6 complex using the PockDrug method 
(Hussein et al., 2015) reveals two ÔdruggableÕ pockets within the 14-3-3 binding groove 
located in the vicinity of HSPB6 residues 13-14 and 17-20 respectively, as well as a third 
pocket within the relatively loose 14-3-3/ACD interface (Fig.5 and Table S2). These findings 
open a perspective of rational design of novel myorelaxant drugs. Firstly, our structural data 
enable the optimization of the small molecules that directly mimic the pHSPB6 binding to 
14-3-3 (An et al., 2011) but are free of the limitations of the peptide-based drug candidates 
such as AZX100¨. Secondly, it appears promising to develop compounds which would 
modulate the interaction of 14-3-3 with the naturally present pHSPB6, rather than 
completely block the primary 14-3-3 binding groove. The strength of this approach is its 
selectivity towards the specific binding partner, i.e. pHSPB6. Supporting such a possibility, a 
recently developed small-molecule stabilizer of the interaction between 14-3-3 and the Gab2 
protein (Bier et al., 2016) was found to bind to our highest-scoring Ôpocket 1Õ (Fig.5).
Discussion
Recent evidence indicates that IDRs play critical roles in protein-protein interactions, 
frequently acting via a phosphorylation-dependent mechanism (Bah et al., 2015; Lee et al., 
2010; Tompa et al., 2015). The interaction between 14-3-3 protein and HSPB6, which is 
involved in the regulation of smooth muscle relaxation, is a prime example of this functional 
paradigm. We have shown here that the pHSPB6 dimer has a submicromolar apparent 
affinity to the 14-3-3 dimer, which exceeds the affinity of an isolated HSPB6 phophopeptide 
by roughly a factor of 10. This pronounced avidity is due to both simultaneous binding of 
two phosphomotifs and a direct interaction between one 14-3-3 subunit and the ACD dimer 
which we could observe in the full complex structure. Given high intracellular 
concentrations of HSPB6 (~1% of soluble protein in muscle (Kato et al., 1994)), its strong 
affinity for 14-3-3 demonstrated here implies that this sHSP, once phosphorylated, can 
indeed act a potent competitor for 14-3-3 binding in the cellular context (Dreiza et al., 2005; 
Sudnitsyna et al., 2012).
The data presented here provide for the understanding of the 14-3-3/pHSPB6 complex 
formation at molecular level. We predict that this process starts with the interaction of one 
phosphoserine-containing motif of the HSPB6 dimer with one of the binding grooves of the 
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14-3-3 dimer (Fig.6). This greatly facilitates the attachment of the second motif, resulting in 
a synergistic, doubly-anchored binding. As the result, the 14-3-3 dimer becomes fully 
engaged, making it unavailable for other phosphopeptide-dependent interactions, while the 
flexible NTDs are likely to still allow for a considerable freedom of the ACD dimer position. 
Thereafter the ACD dimer docks onto the two C-terminal  ?-helices of one 14-3-3 subunit, 
breaking the two-fold symmetry. Notably, simultaneous attachment of both ACDs to both 
14-3-3 chains via the mentioned interface is not possible stereochemically (see Fig.3a). The 
newly formed tight complex is relatively rigid and facilitates further ordering of the NTDs of 
HSPB6, which are confined in a cavity formed by the folded domains of both proteins.
Moreover, the structural characterization of the 14-3-3/pHSPB6 complex gives an 
unprecedented snapshot of a mammalian sHSP. Indeed, within the complex we were able to 
trace 38 amino-acid residues at the N-terminus of human HSPB6, corresponding to more 
than half of the NTD. The latter domain, predicted to be largely disordered in this and other 
sHSPs while in the free form (Weeks et al., 2014), plays an essential role in both 
chaperoning function and the large oligomer formation observed for most sHSPs (Heirbaut 
et al., 2014; Mymrikov et al., 2011). Ordering of the NTDs within the 14-3-3/pHSPB6 
complex follows the principle of induced folding, which appears to be a general feature 
observed upon the interaction of IDR-containing proteins with their partners (Wright and 
Dyson, 2009). As the result, the IDRs can act as Ômolecular rheostatsÕ adjusting their 
structure depending on a particular partner (Flock et al., 2014; Lee et al., 2010), a capacity 
that is likely to be relevant towards the chaperoning function of sHSPs as well. Along the 
same lines, the fact that the 14-3-3/HSPB6 complex deviates from the ÔnaturalÕ two-fold 
symmetry implies that the NTDs of HSPB6 are able to adopt different conformations even 
upon the interaction with the same partner (the two equivalent subunits of 14-3-3), revealing 
an interesting case of the IDRsÕ versatility. Such behavior appears to be a common theme in 
sHSPs, as the large oligomers of human  ?B-crystallin were recently shown to include two 
distinct conformations of its NTD (Mainz et al., 2015), while similar nonequivalence of the 
NTDs has also been observed in yeast (Hanazono et al., 2013) and plant sHSPs (van 
Montfort et al., 2001).
Of particular importance is the observed binding of the highly conserved N-terminal motif 
RLFDQxFG in the shared groove of the ACD dimer. We hypothesize that this interaction is 
an inherent feature contributing to the dimer stability in HSPB6 and most likely other 
mammalian sHSPs. This correlates with our findings on the impact of this conserved motif 
on the functional properties of HSPB6 (Heirbaut et al., 2014). Most interestingly, a class of 
drug-like molecules was recently shown to bind to the same shared groove in  ?-crystallins 
(Makley et al., 2015). Such binding results in  ?-crystallin stabilization and ultimately helps 
to prevent its aggregation, opening a perspective of eye cataract treatment.
Last but not least, the presence of IDRs in all mammalian sHSPs (Weeks et al., 2014) is the 
likely reason why none of them could ever be crystallized in their entirety. Fortuitously, the 
formation of the 14-3-3/pHSPB6 complex leads to partial ordering of the NTDs within the 
cavity made by the 14-3-3 dimer and the asymmetrically bound ACD dimer. This ordering is 
apparently just sufficient to enable the crystal formation, provided the 14-3-3 ? isoform is 
being used, allowing us to resolve this long-standing enigma.
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Experimental Procedures
Synthetic peptides
HSPB6 phosphopeptides and the N-terminal peptide (residues 2 to 10), all without terminal 
modifications and at >98% purity, were obtained from Severn Biotech (UK) and Proteogenix 
(France) respectively. Fmoc chemistry and C18 reverse phase HPLC were used.
Cloning, expression and purification of pHSPB6 constructs
The pET23 vector-based expression construct for the full-length (residues 1-160) wild-type 
untagged HSPB6 was described before (Bukach et al., 2004). In addition, we have used the 
pETHSUL vector (Weeks et al., 2007) to overexpress the ACD of HSPB6 (residues 72 to 
149) as well as its truncated variant (residues 1-149) lacking the CTD. Previously the CTD 
was found largely disordered in the crystal structure of N-terminally truncated HSPB6 
(ΔN56) (Weeks et al., 2014). Finally, another HSPB6 construct including small truncations 
at both N- and C-termini (residues 7-153) was cloned into the pET23 vector.
Phosphorylated HSPB6 constructs were obtained in E. coli by co-expression with protein 
kinase A (PKA). To this end, His-tagged catalytically active subunit of mouse PKA was 
cloned into pACYC vector (chloramphenicol resistance) using NcoI and BamHI restriction 
sites. E.coli C41(DE3) competent cells were simultaneously transformed with the HSPB6 
plasmid (ampicillin resistance) and the latter PKA plasmid under selection on both 
antibiotics. Selected clones were used for expression in 2 l of 3-fold Luria-Bertani media 
supplied with the two antibiotics. After 8 h shaking at 37 ¼C, 0.3 mM isopropyl- ?-D-
thiogalactoside was added to enhance protein expression for another 20-24 h at 30 ¼C.
The untagged full-length pHSPB6 and the 7-153 truncation were purified using ammonium 
sulfate fractionation and ion-exchange and hydrophobic interaction chromatography as 
described earlier (Bukach et al., 2004; Mymrikov et al., 2010; Sluchanko et al., 2011). The 
His-tagged SUMO fusion for pHSPB6(1-149) was purified using subtractive immobilized 
metal-affinity chromatography (IMAC) and gel-filtration essentially as described (Weeks et 
al., 2014). During this procedure, the fusion was cleaved with SUMO hydrolase resulting in 
a target protein without exogenous residues. The obtained samples were fully 
phosphorylated at a single residue Ser16 as verified by fragmentation of 1429.7 Da 
phosphopeptide using tandem mass-spectrometry on a MALDI TOF/TOF ultrafleXtreme 
mass-spectrometer (Bruker, Germany). Purification of the (unphosphorylated) HSPB6 ACD 
construct followed the same procedure as for pHSPB6(1-149).
Isolation of 14-3-3 constructs
Cloning, overexpression and purification of the full-length human 14-3-3 ? and 14-3-3 ?
were described previously (Chernik et al., 2007; Sluchanko et al., 2011). In addition, 
expression plasmids for human 14-3-3 isoforms with truncation of a short disordered region 
at the C-terminus were kindly provided by the laboratory of Christian Ottmann (Eindhoven 
University). These plasmids were used to express the following fragments: 14-3-3 ?(1-231), 
14-3-3 ?(1-230), 14-3-3 ?(1-232), 14-3-3 ?(1-232) and 14-3-3 ?(1-235). The expression 
constructs contained an N-terminal His-tag that was cleaved off at a tobacco etch virus 
Sluchanko et al. Page 9
Structure. Author manuscript; available in PMC 2017 February 22.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
protease site during IMAC-based purification, leaving exogenous residues GAMGS at the 
N-terminus of the final product.
In an attempt to improve crystallization, mutations in 14-3-3 ? protein were designed 
following the surface entropy reduction (SER) approach (Goldschmidt et al., 2007) using an 
online server at http://www.doe-mbi.ucla.edu/Services/SER. The following clusters of triple 
mutations were used: 159KKE161 ᗐAAA, designated Clu1 (top SERp score = 6.17) 
and 75EEK77 ᗐAAA, designated Clu3 (SERp score = 4.73). The mutants were prepared by 
site-directed mutagenesis of the C-terminally truncated 14-3-3 ? protein (1-231), and cloned 
into a modified pET28 vector. The vector contains the N-terminal His-tag followed by a 3C 
protease cleavage site. After subtractive IMAC purification and cleavage, the final products 
retained three exogenous residues GPH at their N-terminus. The triple mutants Clu1 and 
Clu3 have indeed helped to crystallize the complexes of 14-3-3 ?(1-231) with 
pHSPB6(1-149) and the pHSPB6(13-20) peptide, respectively (see Fig. S2b).
All final protein samples appeared as a single band on a Coomassie-stained SDS-PAGE. The 
pure proteins were dialyzed against 20 mM Tris-HCl buffer (pH 7.6) containing 150 mM 
NaCl, 0.1 mM EDTA, 15 mM ME or 2 mM DTT, 0.05 mM PMSF, concentrated on 10 kDa 
cutoff Amicon concentrators (Millipore) and stored frozen at -20 ¼C. Protein concentration 
was determined spectrophotometrically at 280 nm.
Isothermal titration calorimetry
The binding of the pHSPB6(11-23) phosphopeptide to either 14-3-3 ? or 14-3-3 ? was 
analyzed using a MicroCal iTC200 System (GE Healthcare Life Sciences, USA) at 30 ¡C in 
a 20 mM Tris-HCl buffer (pH 7.6) containing 150 mM NaCl, 0.1 mM EDTA and 2 mM  ?-
mercaptoethanol. 2 µl aliquots of the 14-3-3 protein were injected into the 0.2 ml cell 
containing the phosphopeptide to obtain a complete binding isotherm. Concentration of 
pHSPB6(11-23) in the cell was either 44 µM (titrated by 0.5 mM 14-3-3 ?) or 100 µM 
(titrated by 1 mM 14-3-3 ?). Measurements have been repeated at least three times with a 
variation of protein and peptide concentrations. The obtained data were corrected for heat of 
dilution measured by injecting 14-3-3 into a buffer solution. Titration curves were fitted 
using MicroCal Origin 9.0 software.
Fluorescence spectroscopy
Full-length HSPB6 was phosphorylated by PKA in vitro (Sluchanko et al., 2011) and 
stoichiometric phosphorylation at the Ser16 residue (Beall et al., 1999) was confirmed by 
native gel electrophoresis. Thereafter the pHSPB6 sample was buffer-exchanged into 20 mM 
HEPES buffer (pH 7.5) containing 100 mM NaCl. To reduce the SH groups, 20 mM DTT 
was added for 20 min at room temperature and then its excess was removed by using NAP-5 
(Illustra, GE Healthcare) desalting columns. Immediately afterwards, a 6-fold molar excess 
of fresh aqueous solution of 5-[2-(Iodoacetamido)ethylamino]naphthalene-1-sulfonic acid 
(1,5-I-AEDANS) was added and incubated for 1h at room temperature and then overnight at 
4 ¡C. After removal of the unbound label using an ultraconcentration device (Millipore) and 
subsequently a NAP-5 column, the extent of labeling was estimated spectrophotometrically 
at 336 nm using extinction coefficient of AEDANS of 5700 M-1 cm-1, and reached 90%. 
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AEDANS fluorescence was followed using a Cary Eclipse spectrofluorometer (Varian Inc.) 
equipped with a thermocontrolled multicell holder. Titration of AEDANS-labeled 
phosphorylated HSPB6 by human 14-3-3 ?(1-231), added in 1-2 µl portions, mixed by 
pipetting and allowed to equilibrate for 5 min, was performed in quartz cuvettes (600 µl) at 
30¡C. The experiments were also done in the presence of the HSPB6 11-23 phosphopeptide. 
The peptide contains one native tryptophan residue (Trp11), enabling an accurate 
determination of its concentration by absorbance at 280 nm. Titration curves were buffer-
corrected and then fitted using MicroCal Origin 9.0 software by either a classical quadratic 
equation (in the absence of phosphopeptide) or, in a competition assay, by a cubic equation 
according to the method by Wang (Wang, 1995), to estimate the apparent binding constant.
Crystallization
Initial search for crystallization conditions was done using commercial screens including 
PACT, Procomplex (Qiagen), Wizard I+II (Emerald BioStructures), Index (Hampton 
Research) and JCSG+ (Molecular Dimensions). Sitting drops containing 0.2 µl protein at 
above 10 mg/ml concentration (See Table S1) and 0.2 µl precipitant solution were set up in 
96-well plates using a Mosquito robot (TTL Labtec). The crystallizations were incubated at 
either 4 or 20 ¼C and monitored using a RockImager 1000 (Formulatrix). Crystallization 
optimization was performed manually in 1-2 µl sitting drops.
To form the 14-3-3/phosphopeptide complexes prior to crystallization, an 14-3-3 isoform (in 
50 mM Tris buffer, pH 7.5, containing 150 mM NaCl, 0.1 mM EDTA, 2 mM MgCl2 and 2 
mM DTT) was supplemented with 2 to 6-fold molar excess of the pHSPB6 (13-20) or 
(11-23) phosphopeptide.
The complexes of 14-3-3 proteins and phosphorylated HSPB6 variants were prepared and 
purified using size-exclusion chromatography (SEC) immediately before crystallization 
essentially as described in (Chernik et al., 2007). Briefly, the individual proteins were mixed 
at 1.2-1.5 molar excess of pHSPB6 and incubated for 15-20 min at 30-37 ¡C. The sample 
was then concentrated to above 10 mg/ml and loaded on a Superdex 200 column (120 ml) 
equilibrated with 50 mM HEPES buffer (pH 7-7.5), 150 mM NaCl, 0.1 mM EDTA and 2 
mM DTT. The main peak corresponding to the stable 2:2 complex was concentrated and 
used for crystallization. Different combinations of 14-3-3 isoforms and truncation or 
deletion constructs of phosphorylated HSPB6 were tested. All 7 isoforms of 14-3-3 ( ?,  ?,  ?, 
 ?,  ?,  ?,  ?) formed stable complexes with all pHSPB6 constructs. However, no crystals could 
be obtained unless the 14-3-3 ? isoform was used. The presence of both partners in the 
crystals was confirmed by SDS-PAGE. After optimization, macrocrystals could be 
reproducibly grown within several days for the complex of 14-3-3 ?(1-231) with each of the 
following pHSPB6 variants: full-length (1-160), 1-149 and 7-153. The exact pHSPB6 
construct was not significant. Two crystal forms both diffracting to 6-8 resolution were 
obtained: prisms in the space group P6x22 and plates in the space group C2221. Using the 
above-described Clu1 and Clu3 triple SER mutants of 14-3-3 ?(1-231) for complex 
formation did not result in any radical changes in the crystalsÕ appearance, but however 
somewhat improved their diffraction quality.
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Finally, the N-terminal peptide of HSPB6 in powder form was added to the HSPB6 ACD 
solution in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl to achieve about ~3x molar excess of 
the peptide prior to crystallization.
Optimized crystallization conditions for all complexes are given in Table S1.
X-ray data collection
Diffraction data (Table 1) were collected at 100K using 0.98 radiation at Proxima 2a 
beamline of Synchrotron Soleil (France) by means of ADSC Quantum 315 and Eiger 9M 
dectors. Crystals were mounted on nylon loops and flash-cooled in liquid nitrogen. For all 
crystals, the precipitant solution was supplemented with 15-20% ethylene glycol for 
cryoprotection. For the 14-3-3/pHSPB6 complexes, multiple data collection sessions were 
alternated by further attempts to improve crystal quality, including additives, growth 
temperature variation, seeding, dehydration, alternative cryoprotectants and crosslinking, 
with limited success. The best data were eventually obtained using 14-3-3 ? Clu1 (1-231)/
pHSPB6(1-149) plates with a size of about 150x100x30 µm3. Screening many similar 
crystals, as well as the use of the helical data collection protocol at the microfocus beamline 
were necessary.
Crystal structure solution and refinement
Diffraction data integration and scaling were performed using XDS/Xscale (Kabsch, 2010) 
and Xdsme (Legrand, 2009). Phasing of the 14-3-3 ?/peptide complexes was done by 
molecular replacement in MolRep (Vagin and Teplyakov, 2010) using a 14-3-3 ? dimer from 
the PDB entry 3IQJ as a search model. The HSPB6 ACD / N-peptide complex was also 
phased by molecular replacement using the ACD extracted from the crystal structure of 
HSPB6 ΔN56 fragment (PDB entry 4JUT). Automated refinement was carried out with 
Buster (Blanc et al., 2004). Manual model correction was done in Coot (Emsley and 
Cowtan, 2004). The quality statistics of the final models is given in Table 1. Phasing of the 
14-3-3 ? Clu1 (1-231)/pHSPB6 (1-149) complex was done in MolRep using a dimeric 
14-3-3 ?/pHSPB6(13-20) peptide complex as a search model, initially positioning three of 
them. Thereafter a MolRep real-space search (i.e. in a map calculated with the available 
phases) using an HSPB6 ACD dimer from PDB entry 4JUT could position three such 
dimers. The missing N-terminal regions of HSPB6 were added in Coot on the basis of 
difference electron density maps. Subsequent refinement in Buster included a rigid-body 
positional refinement of all chains, followed by an all-atom refinement with additional 
restraints provided by the non-crystallographic symmetry as well as by the ÔtargetÕ high-
resolution structures. To this end, the refined 14-3-3 ?/pHSPB6(13-20) complex (2.4 
resolution) and the HSPB6 ACD / N-peptide complex (2.6 resolution) were used. Only the 
overall temperature factors, together with the TLS parameters per each domain, were 
refined. After the structure of the 14-3-3 ? Clu1 (1-231) / pHSPB6 (1-149) complex had been 
established, using rigid-body refinement against the data for both the 14-3-3 ? Clu1 (1-231) / 
full-length pHSPB6 and the 14-3-3 ? Clu1 (1-231) / pHSPB6 (7-153) complexes we could 
confirm the same overall structure, but no further refinement was carried out due to limited 
resolution (<7) of the data. All structural figures were prepared using Pymol 1.6.9 
(Schrdinger), which included calculations of the electrostatic potential using adaptive 
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Poisson-Boltzmann solver plug-in for Pymol (Baker et al., 2001). Atomic coordinates and 
structure factors have been deposited to PDB under the assession codes indicated in Table 1.
Limited proteolysis
Purified pHSPB6 (1 mg/ml), its mixture with 1.2 molar excess of untagged 14-3-3 ?, or the 
same amount of 14-3-3 ? alone were pre-incubated for 30 min at 37 ¡C. Thereafter tosyl 
phenylalanyl chloromethyl ketone (TPCK) treated trypsin was added at protease:pHSPB6 
ratio of 1:1500. The cleavage was at 37 ¡C in 20 mM Tris-HCl buffer, pH 7.6, containing 
150 mM NaCl, 0.1 mM EDTA and 15 mM ME. At various time intervals the reaction was 
stopped by addition of the SDS-PAGE sample buffer containing 2.5 mM PMSF as quencher. 
The samples were boiled and analyzed on SDS-PAGE (12-20% polyacrylamide), and 
additionally desalted and analyzed using MALDI TOF/TOF ultrafleXtreme mass-
spectrometer (Bruker, Germany). Quantitative densitometric analysis of the bands was 
performed using ImageJ 1.48. The bands resulting from the cleavage at residues R27 and 
R32, although discernible on the gels (Fig. S3), were integrated together in Fig.4a.
SAXS data collection and processing
SAXS data for the SEC-purified 14-3-3 ?(1-231)/pHSPB6 (1-149) complex at different 
concentrations (1-9 mg/ml) in 50 mM TRIS buffer (pH 7.5) with 150 mM NaCl, 0.1 mM 
EDTA and 2 mM DTT were recorded for the momentum transfer range 0 < s < 0.5 -1, 
where s = 4 ? sin  ?/ ?,  ? being the scattering angle. The data were collected at 283 K using 
radiation with  ?= 1.2 at the BM29 beamline (ESRF, Grenoble) equipped with a Pilatus 
1M detector (Dectris, Baden, Switzerland). No significant radiation damage was detected. 
Even though the dependence of the concentration-normalized scattering profiles on sample 
concentration was only minor, the data were taken to produce the infinite dilution-
extrapolated curve using the program Almerge from the ATSAS 2.6.0 package (Petoukhov 
et al., 2012). To create a complete atomic model of the complex, the crystal structure was 
first supplemented by a C ?-trace of the missing parts of the NTD using multiple runs of the 
program Coral (Petoukhov et al., 2012) towards an optimal fit to the SAXS data in a range 
of 0 < s < 0.3 -1. This involved the residues 39-69 in the type I chain and residues 1-12 and 
21-69 in the type II chain, totalling to ~11% of the complex mass. The resulting models 
were validated against the SAXS curve for the full range of scattering data using Crysol 
(Petoukhov et al., 2012). This procedure showed a good convergence, as a cluster of 
obtained models yielded a good match to the experimental data, with the  ?2 ranging 
between 2.3 and 3. 8 (Figs.S4b,c), and the model radius of gyration Rg between 30.6 and 
30.7. Two ways of interconnecting the ordered N-terminal parts and the two ACDs of the 
crystallographic complex have been tried and yielded comparably good-fitting models. 
Thereafter the BBQ script of Bioshell package (Gront and Kolinski, 2006) and the program 
Scwrl 4.0 (Krivov et al., 2009) were used to convert the C ?-trace of the best-fitting Coral-
derived model to a full-atom model, resulting in final  ?2 = 2.2 (Fig. 4b). In addition, we 
have noticed that the size of the ACD dimer matches the cavity formed by the 14-3-3 dimer, 
and used a rigid-body docking to construct an alternative symmetric model of the complex 
(Fig. S5). However, even after modeling of the missing parts of the NTD using Coral this 
alternative model failed to produce any reasonable fit to the experimental SAXS data ( ?2 = 
169).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
¥ X-ray structure of the 14-3-3/pHSPB6 heterotetrameric complex was obtained
¥ N-terminal domain of HSPB6 becomes partially ordered within the complex
¥ Synergistic binding explains effective sequestering of 14-3-3 by pHSPB6
¥ First-ever atomic resolution snapshot of a human small HSP in a functional 
state
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Figure 1. Interaction of 14-3-3 ? with HSPB6 phosphopeptides.
a. A schematic diagram of HSPB6. Within its NTD, the 14-3-3 binding motif and the 
conserved motif 27RLFDQxFG34 are highlighted in orange and yellow, respectively. Below 
are the sequences of two phosphopeptides used in this study and of the therapeutic 
phosphopeptide AZX100. b. ITC data for the interaction of 14-3-3 ? with the 
pHSPB6(11-23) phosphopeptide. c. Crystal structure of the 14-3-3 ? dimer with the bound 
pHSPB6(11-23) (orange). A close-up to the right shows the 2Fo-Fc electron density map for 
the phosphopeptide (grey mesh, contoured at 1 ?), ordered waters (w1, w2, magenta) and 
hydrogen bonds/salt bridges (dashed lines).
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Figure 2. Interaction of AEDANS-labeled phosphorylated HSPB6 with 14-3-3 ? studied by 
fluorescence spectroscopy.
a. Changes in the AEDANS fluorescence spectrum (excitation at 336 nm) for 4.2 µM 
pHSPB6AEDANS solution upon titration with increasing concentrations of 14-3-3 ? as 
indicated (in µM, colored lines). b. Changes in fluorescence intensity (ΔF) at 488 nm upon 
titration of 4.2 µM pHSPB6AEDANS solution by 14-3-3 ? in the absence of the HSPB6 
phosphopeptide 11-23, followed (at the time point indicated by an arrow) by titration with 
phosphopeptide. Alternatively, ΔF was measured for 4.2 µM (red line, circles) or 2.8 µM 
(blue line, triangles) pHSPB6AEDANS solution supplemented with 4.2 µM or 20 µM 
phosphopeptide, respectively, and titrated with 14-3-3 ?. See also Fig. S1.
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Figure 3. Crystal structure of the 14-3-3 ?/pHSPB6 regulatory complex.
a, b. Ribbon diagram of the heterotetramer shown in two perpendicular views (second 
14-3-3 molecule omitted in panel b for clarity). The ordered parts of the HSPB6 NTDs of 
type I and II are colored red and magenta, respectively. Important residues are labeled. The 
semi-transparent surfaces of 14-3-3 dimer and ACD dimer are also shown. Due to 
disordering of residues 39 to 69 there is ambiguity in the interconnection of the N-terminal 
parts and the ACDs: the NTD of type I could connect to the yellow-colored ACD and the 
NTD of type II to the orange-colored ACD (as indicated by dashed lines in panel b), or vice 
versa. c.  ?4/ ?8 groove patching observed in the co-crystals of the HSPB6 ACD with the N-
terminal peptide 2EIPVPVQPS10. For clarity, only one ACD chain is shown. An Fo-Fc 
difference (omit) map for the peptide is shown at 2.6 resolution, contoured at 2.5 ?(green 
mesh). d. Patching of the shared  ?3/ ?3 groove of the ACD dimer by the conserved region of 
the NTD, as observed in the 14-3-3 ?/pHSPB6 complex. A corresponding 4.5 resolution 
difference (omit) map is shown at 2.5 ? contour level (green mesh). e. A close-up of the 
shared groove patching. A semitransparent surface of the ACD dimer is colored by 
electrostatic potential from -1 (red) to +1 kT/e (blue). See also Fig. S2.
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Figure 4. Analysis of the 14-3-3/pHSPB6 complex in solution.
a. Time course of trypsinolysis of pHSPB6 alone (dashed lines) and in complex with 
14-3-3 ?(solid lines), showing the evolution of band intensities for intact pHSPB6 and its 
cleavage products at indicated sites. All band intensities are expressed as a percentage of the 
intact pHSPB6 band at zero time. See also Fig. S3. b. Solution SAXS curve for the complex 
(grey circles) overlaid by the calculated scattering from the full atomic model (red line). c. A 
cartoon of the full model, including the crystal structure (14-3-3 ? dimer in blue, HSPB6 
ACD dimer in green and the ordered parts of the NTD in red) supplemented with the flexible 
parts of the NTD (yellow). See also Figs. S4, S5.
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Figure 5. ÔDruggableÕ pockets in the 14-3-3 ?/pHSPB6 complex.
a. View of the 14-3-3 ? groove (semi-transparent surface) which accommodates the 
pHSPB6(13-20) peptide (green sticks). Analysis using the PockDrug method (Hussein et al., 
2015) reveals two druggable pockets at either end of the bound phosphopeptide (pockets 1 
and 2 coloured pink and violet, respectively). b. Another prominent druggable pocket 
(pocket 3, cyan) is found at the 14-3-3 ?/ACD interface. See also Table S2.
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Figure 6. Proposed mechanism of the 14-3-3/pHSPB6 regulatory complex formation.
Key regions of the HSPB6 NTD are labeled as follows: N, the N-terminal region (residues 
1-10); P, the 14-3-3-binding region (residues 13-20) including the phosphoserine 16; C, the 
ÔcentralÕ conserved region (residues 27-34). One of the two central regions may occupy the 
shared  ?3/ ?3 groove of the ACD dimer already in the free state. a. The first phosphomotif of 
dimeric pHSPB6 binds in the groove of one 14-3-3 subunit. b. The second phosphomotif 
binds to the other 14-3-3 subunit. c.The ACD dimer docks onto the C-terminal lobe of the 
proximal 14-3-3 subunit (double-sided arrows), which induces ordering of additional N-
terminal residues of the engaged HSPB6 chain (solid lines), resulting in a compact assembly. 
The second NTD is accommodated in the cavity formed and is likely to undergo partial 
ordering as well.
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Table 1
X-ray data collection and refinement statistics (See also Table S1).
14-3-3 ? Clu3 
(1-231) / pHSPB6 
(13-20) peptide
14-3-3 ? WT 
(1-231) / pHSPB6 
(11-23) peptide
14-3-3 ? Clu1 (1-231) / 
pHSPB6 (1-149) #
HSPB6 ACD / N-
peptide
Data collection
Space group P21 C2 C2221 P3122
  Cell dimensions: a, b, c () 55.6, 104.0, 123.1 90.1, 79.0, 75.4 125.1, 341.3,144.6 105.7, 105.7,112.0
                             ?,  ?,  ?(¡) 90, 93.9, 90 90, 102.5, 90 90, 90, 90 90, 90, 120
Resolution range () 1 48 - 2.4
[48-11] (2.46-2.4)
43 - 2.5
[43-11] (2.56-2.5)
48 - 4.5
[48-20] (4.62-4.5)
48 Ð 2.6
[48-12] (2.67-2.6)
Rmerge 2 0.099[0.032] (1.53)
0.150
[0.040] (1.82)
0.314
[0.066] (2.16)
0.088
[0.029] (2.68)
Rmeas 0.116
[0.038] (1.79)
0.175
[0.051] (2.12)
0.337
[0.072] (2.23)
0.093
[0.031] (2.81)
<I /  ?> 8.6
[25.9] (0.9)
7.1
[22.4] (0.9)
5.8
[22.2] (1.1)
18.2
[63.5] (0.9)
CC1/2 1.00 (0.62) 1.00 (0.60) 0.99 (0.34) 1.00 (0.51)
Completeness (%) 99.7 (100) 99.6 (100) 99.6 (99.9) 100 (100)
Redundancy 3.7 (3.8) 3.7 (3.8) 7.9 (8.1) 11.3 (11.3)
Refinement
No. of reflections: total 54511 17876 18722 22684
                     ÔfreeÕ set 2718 1040 934 1097
Rwork (%) 3 18.5 20.9 23.6 20.7
Rfree (%) 3 21.4 25.0 25.6 22.7
No. of 2:2 complexes /asu 2 1 3 2.5
No. of non-H atoms: protein/ion/water 7409 /32 /361 3733 /0 /127 15845 /48 /0 3375 /20 /14
Solvent content (%) 62 48 60 67
R.m.s.d. bond lengths ()/angles (¡) 0.010 / 1.6 0.010 / 1.2 0.008 / 1.1 0.010 / 1.3
Ramachandran favoured/outlier (%) 97.7 / 0.1 97.4 / 0.2 93.9 / 0.8 95.4 / 0.5
Molprobity score / percentile 1.32 / 99th 1.55 / 99th 2.23 / 100th 2.12 / 95th
PDB code 5LU1 5LU2 5LTW 5LUM
1
Statistics for the lowest and highest resolution shells are indicated in square brackets and parentheses, respectively
2
All merging statistics as defined in XSCALE (Kabsch, 2010)
3
As defined in Buster (Blanc et al., 2004).
#
Isomorphous crystals could be obtained for the 14-3-3 ? Clu1 (1-231) complexes with either pHSPB6(1-149) truncation, full-length pHSPB6 
(1-160), or the 7-153 truncation but in the two latter cases the diffraction never exceeded 7.
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